Navigation Links
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Date:11/15/2007

- Trial CL-05 Results Showed Cethromycin had 94.0% Clinical Cure Rate Compared to 93.8% Clinical Cure Rate for Biaxin(R), a Current Standard of

Care Treatment - - Trial CL-05 and Trial CL-06 to Form the Core of New Drug Application -

CHICAGO, Nov. 15 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States. The primary efficacy endpoint of statistical non-inferiority in the clinical cure rate at the test-of-cure visit was achieved. The study results showed that cethromycin cured 94.0% of patients with CAP, compared to Biaxin(R) (clarithromycin), a current standard of care treatment for CAP, which cured 93.8% of studied patients in the per protocol population. In the modified intent to treat population, cethromycin cured 83.1% of patients and Biaxin cured 81.1%. Cethromycin also demonstrated favorable safety results, with reported side effects similar to or less than those seen with Biaxin.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO )

"We are very excited to have met all of our endpoints in Trial CL-05, and we are pleased to have successfully completed the clinical development program of cethromycin. The results attained in this trial, along with the positive results achieved in Trial CL-06 reported in June of this y
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
4. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
6. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , Sept. 23, 2014 Galmed Pharmaceuticals ... clinical-stage biopharmaceutical company focused on the development and ... treatment of liver diseases and cholesterol gallstones, announced ... or the FDA, approved its request for Fast ... the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... -- Vesselon, Inc. today announced the appointment of Jurgen Raths, ... 2014. Dr. Raths, appointment follows Vesselon,s engagement with Spencer ... a private preferred Series A round to facilitate development ... "Jurgen,s deep experience across multiple functional areas of medical ... as we develop our device that can be compared ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... 2011 Express Scripts (Nasdaq: ESRX ), one ... announced today its intention to release its third quarter earnings ... will hold its quarterly conference call to discuss third quarter ... Time (8:30 a.m. Central Time). This call is ...
... U.S. Food and Drug Administration has issued a proposed ... classification for external pacemaker pulse generators from Class III ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) External pacemaker pulse generators are ... permanent pacemaker can be implanted. They are also used ...
Cached Medicine Technology:FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 2FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 3
(Date:9/23/2014)... Mich. They are common suggestions to remedy stress: You ... Get out and see people. , Turns out ... better a lot better a new large scale ... lower depression, less perceived stress and enhanced mental health and ... Michigan, with partners from De Montfort University, James Hutton Institute, ...
(Date:9/23/2014)... ANGELES (September 23, 2014) Laparoscopic cholecystectomy, a minimally ... the most common abdominal surgeries in the U.S. Yet ... to the procedure with some moving patients quickly into ... online Monday in the American Journal of Surgery ... regular working hours rather than rushing the patients into ...
(Date:9/23/2014)... living things function comes from knowledge of structuresatomic details ... receptors that are docking stations for viruses and messenger ... carry genetic blueprints for building cellular machinery, to name ... structural details, a new grant just awarded by the ... of Energy (DOE) will fund the operation of a ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry expert ... is a 13-year veteran in the school, commercial and transit ... Bus Sales of Colton, California. While with A-Z Mr. Reynolds ... line revenues, profit and market penetration by double digits. , ... all-electric or plug-in hybrid vehicle conversions. They have converted ...
(Date:9/23/2014)... the European Journal of Cancer presents detailed ... the 1st EORTC Cancer Survivorship Summit held this past ... and more personalized multimodal treatments has boosted survival rates ... and rapidly increasing number of cancer survivors. Despite this ... broad spectrum of late adverse treatment effects and some ...
Breaking Medicine News(10 mins):Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:Study finds gallbladder surgery can wait 2Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2
... disease are there, researchers say , WEDNESDAY, Oct. 24 (HealthDay ... show early signs of heart disease -- similar to that ... by a team at Washington University School of Medicine, St. ... the children had undergone cardiac ultrasound to check on symptoms ...
... break-through new way of ... taking daily dose of glucosamine, SAN FRANCISCO, Oct. 24 ... wants to help,people keep their joints hydrated and moving smoothly.* The ... Joint Juice products: -- Original Joint Juice: ready-to-drink juice-based dietary ...
... ), the,global leader in the development, manufacture and supply ... today that it,will broadcast a third quarter 2007 earnings ... 2007 at 10:00 a.m. EDT. The call will,last approximately ... the opportunity to listen to,the conference call live at ...
... FRANCISCO While some targeted therapies drugs ... pathways occurring within cancer cells work well by ... when teamed with other targeted and conventional therapies. ... Molecular Targets and Cancer Therapeutics, multiple-target applications of new ...
... Out of Pocket Expenses ... for Medical Foods, ... BMRN) announced today that it has,provided a $250,000 grant to the ... program for patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds ...
... 24 NutraCea (OTC Bulletin,Board: NTRZ), a health ... bran (SRB) nutrient research and technology whose products ... benefits for,humans and animals announced today that it ... relations services and an expanded,communications program among the ...
Cached Medicine News:Health News:Obesity Can Hurt Kids' Hearts 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 3Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 2Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 3
... automated semen analysis, with accurate, consistent, reliable ... Automation provides standardization and ease of use ... analysis. SPERMALITE is a new-generation automated semen ... analysis, and a hard -copy analysis report ...
Stainless Steel. Sterile. 2 pieces/box...
... Cannulated Screw System is part ... systems developed by DePuy ACE ... 3.5mm to 8.0mm. Complete with ... system was designed with the ...
... The first FDA-cleared third-generation allergy test , ... blood testing. It provides quantitative determination of ... excellent precision, accuracy and lot-to-lot reproducibility. The ... hour to help you identify, monitor and ...
Medicine Products: